Press Releases

NEW YORK, N.Y. — June 2. Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis.  Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation (Novartis) conduct the trials through the […] READ MORE

The Lupus Landmark Study, the largest prospective observational study in lupus, will enroll 3,500 patients throughout North America over five years The Lupus Landmark Study is a key component of the Lupus Nexus, a first-of–its-kind in lupus registry, biorepository and data/knowledge portal  NEW YORK, NY (May 23) – The Lupus Research Alliance and its clinical […] READ MORE

Winning projects will explore new potential treatment approaches to prevent lupus from developing or prevent or slow disease progression. New York, NY, April 20. The Lupus Research Alliance (LRA) today announced the newest Lupus Mechanisms and Targets Award grant recipients. The winning four projects collectively test potential treatment approaches to prevent lupus from developing or […] READ MORE

Lupus Accelerating Breakthroughs Consortium to address challenges impacting lupus trial success and to accelerate treatment breakthroughs  Washington, DC, March 29, 2023 – The Lupus Research Alliance (LRA) today announced the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), a first-of-its-kind public-private partnership bringing people with lupus together in collaboration with the U.S. Food and Drug Administration (FDA), […] READ MORE

New York, NY, March 23, 2023. The Lupus Research Alliance (LRA) today announced the recipients of the newest Lupus Innovation Award (LIA) grants. Collectively, the seven projects led by research teams from the U.S. and Europe explore multiple components of lupus, focusing on its causes and the development of more personalized approaches to lupus treatments. […] READ MORE

NEW YORK, NY. January 17— The Lupus Research Alliance (LRA) is pleased to announce the appointment of Stacie J. Bell, PhD as Executive Vice President to lead Lupus Therapeutics (LT), the organization’s clinical research affiliate. An accomplished research scientist and organizational leader, Dr. Bell comes to Lupus Therapeutics with more than 25 years of experience […] READ MORE

NEW YORK, NY, Dec. 14, 2022. The Lupus Research Alliance (LRA) proudly announces the two outstanding recipients of the 2022 Distinguished Innovator Award (DIA): Hongbo Chi, PhD, and Joseph Craft, MD. Both awards are focused on studying distinct T cell populations in lupus which aligns with LRA’s strategic objective to accelerate breakthrough treatments and ultimately […] READ MORE

New York, NY. November 22, 2022 – Last night’s Lupus Research Alliance (LRA) Breaking Through Gala at Manhattan’s historic Ziegfeld Ballroom was both inspiring and successful, raising more than $4 million for lupus research. More than 600 people turned out to recognize 2022 Gala honoree Leslie D. Hale, President & Chief Executive Officer at RLJ […] READ MORE

ACR Convergence 2022 Included LRA-Authored Research on Measures to Demonstrate Treatment Efficacy for Patients with Lupus NEW YORK, NY–November 8, 2022 — The Lupus Research Alliance and its affiliate Lupus Therapeutics will present data at ACR Convergence 2022 with results showing the effectiveness of a pilot peer education program called the Patient Advocates for Lupus […] READ MORE

NEW YORK, NY – August 24, 2022 – The Lupus Research Alliance (LRA) today announced its Global Team Science Award (GTSA) has been granted to three international research teams from 14 institutions across four continents comprised of leading experts spanning in immunology, rheumatology, neurosciences, biomedical engineering, genomics and genetics, and public health. With $3 million […] READ MORE

NUEVA YORK, NY. 10 de agosto de 2022. Lupus Research Alliance (LRA) se complace en anunciar el nombramiento de Albert Roy como presidente y director ejecutivo a partir del 6 de septiembre de 2022. El Sr. Roy actualmente se desempeña como director ejecutivo de Lupus Therapeutics, la filial que se encarga de los ensayos clínicos […] READ MORE

NEW YORK, NY. August 10, 2022 – The Lupus Research Alliance (LRA) is pleased to announce the appointment of Albert Roy to President and Chief Executive Officer effective September 6, 2022. Mr. Roy currently serves as Executive Director of Lupus Therapeutics, the clinical trial affiliate of the Lupus Research Alliance. He will succeed Kenneth M. […] READ MORE